Clark Ian T's Form 4 filing
Guardant Health, Inc. (GH) · filed Jun 20, 2025
- Accession no.
- 0001576280-25-000193
- Filed
- Jun 20, 2025
- Trade date
- Jun 17-18, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $322.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Clark Ian TCIK 0001336504 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2025 | Common Stock | SSaleDisposed | −6,672 | $48.38F1 | −$322,791.36 | 9,851 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | Common Stock | AGrant or awardAcquired | +6,833 | $0.00 | $0 | 6,833 | Direct | |
| Jun 18, 2025 | Common Stock | AGrant or awardAcquired | +5,092 | $0.00 | $0 | 5,092 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.38 to $48.41 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.